Recursion Pharmaceuticals (NASDAQ:RXRX) stock is one of those lesser-known mid-cap biotech plays that investors may be ...

5-year dividend growth rates can be a good indicator for future earnings and upside valuation, so when they are consistent ...

The S&P Dividend Aristocrats ETF (NOBL) may be trailing the rest of the market in the past two years, but the above-average yield (2.1%), track record of long-time dividend growers, and value focus ...